Research

In honor of our 30th anniversary, we’re catching up with former grant recipients to hear how their work has impacted kidney cancer care and research. Dr. Xiao Wei received the 2018 Andrew C. Novick & P.H.M de Mulder Research Scholar Award. She is a physician at the Dana-Farber Cancer Institute and an Instructor in medicine at Harvard Medical School in Boston,…

In honor of our 30th anniversary, we’re catching up with former grant recipients to hear how their work has impacted kidney cancer care and research. Dr. Thai Ho is a medical oncologist, internist, and an Associate Professor in the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona. Dr. Ho received the 2011 ASCO Conquer Cancer Foundation Young Investigator Award while…

In honor of our 30th anniversary, we’re catching up with former grant recipients to hear how their work has impacted kidney cancer care and research. Dr. Raj Gopal is a clinician and researcher at Massachusetts General Hospital in Boston, Massachusetts. He received a 2016 ASCO Conquer Cancer Young Investigator Award, supported by the Kidney Cancer Association. We spoke to Dr. Gopal about…

In honor of our 30th anniversary, we’re catching up with former grant recipients to hear how their work has impacted kidney cancer care and research. Dr. Pooja Ghatalia is a medical oncologist and researcher at Fox Chase Cancer Center and Assistant Professor in the Department of Hematology/Oncology at the Lewis Katz School of Medicine at Temple University in Philadelphia, Pennsylvania. She received…

In honor of our 30th anniversary, we're catching up with former grant recipients to hear how their work has impacted kidney cancer care and research. Dr. Pavlos Msaouel is a clinician and cancer biologist at MD Anderson Cancer Center in Houston, Texas. He received a 2017 ASCO Young Investigator Award supported by the Kidney Cancer Association and was a 2018…

In Louisiana, more people get kidney cancer and more people die of kidney cancer compared to the rest of the United States. But Dr. Pedro Barata and his colleagues at Tulane University School of Medicine in New Orleans are working to change that. By strengthening outreach and education for both community-based oncologists and their patients and growing a rigorous clinical…

Kidney cancer research highlights presented at the 2020 meeting of the American Society of Clinical Oncology (ASCO). Cancer patients suffer more from COVID-19 Cancer patients who become ill as a result of the novel coronavirus COVID-19 are more likely to die within a month compared to people without cancer and have more complications like intubation, according to two studies published…

Mike Kelly, 67, was diagnosed with stage IV clear cell renal cell carcinoma (RCC) last fall and had a nephrectomy to remove his left kidney at MD Anderson Cancer Center (MDACC) in Houston, Texas soon after. Kelly also began participating in a clinical trial early in 2020 for which he takes the tyrosine kinase inhibitor Cabometyx® (cabozantinib). Already attentive to…

In the phase III CheckMate-9ER trial, nivolumab (Opdivo) plus cabozantinib (Cabometyx) combined improved overall survival (OS) and progression-free survival (PFS) compared with sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC) who had not previously received treatment. “The results from the pivotal CheckMate -9ER trial clearly demonstrate the combination of cabozantinib plus nivolumab provides a clinically meaningful benefit in…

During these challenging days, I've been searching for any possible positives that might come out of this healthcare crisis we're in together. Here are a few: Possibly we will learn that less immunotherapy (fewer doses) will be equally effective as the doses that were originally tested and approved. For years there have been whispers in the hallways that we may…